Results 71 to 80 of about 3,975 (165)

The Caribbean, Central and South America Network for HIV Epidemiology: 20 Years of HIV Research in the Region

Journal of the International AIDS Society, Volume 29, Issue S3, July 2026.
ABSTRACT Introduction Latin America is a key region in advancing efforts to end the HIV epidemic globally. Despite breakthroughs in HIV treatment and prevention in the last 20 years, as well as region‐wide improvements in health infrastructure and policies, there has been a 13% increase in new acquisitions in Latin America from 2010 to 2024.
Jessica L. Castilho, Stephany N. Duda, Bryan E. Shepherd, Timothy R. Sterling, Anna K. Person, Peter F. Rebeiro, William C. Wester, John R. Koethe, Jesse Carlson, Rachael A. Pellegrino, Karu Jayathilake, Fernanda Maruri, Hilary Vansell Riley, Amanda Garcia De Matos Amaral, Marina Cruvinel Figueiredo, Paridhi Ranadive, Megan Turner, Gustavo Amorim, Vickie Myers, Heather Burgess, Shengxin Tu, Liping Du, Danni Shi, Zhouhui Liang, Kaixing Liu, Chao Yan, Beatriz Grinsztejn, Valdilea G. Veloso, Paula M. Luz, Sandra Wagner Cardoso, Ruth Friedman, Ronaldo I. Moreira, Monica Derrico Pedrosa, Hugo Perazzo, Rodrigo Moreira, Maria Pia Diniz Ribeiro, Mario Sergio Pereira, Emilia Moreira Jalil, Thiago Silva Torres, Carolina Coutinho, Mayara Secco Torres Silva, Flaviana Pavan Victoriano, Jorge Pinto, Flavia Ferreira, Marcelle Maia, Victoria Bocardi, Julia Caporali, Flavia Fonseca, Mateus Westin, Regina Célia de Menezes Succi, Daisy Maria Machado, Aida de Fátima Barbosa Gouvêa, Fabiana Bononi do Carmo, Claudia P. Cortes, Maria Fernanda Rodriguez, Gabriel Castillo‐Rozas, Fabio Paredes, Georgina Estadella, Jean William Pape, Vanessa Rouzier, Adias Marcelin, Jodany Bernadin, Stanley Cadet, Marco Tulio Luque, Diana Varela, Magda Chavez, Ada Mailhot, Eduardo Gotuzzo, Fernando Mejia, Gabriela Carriquiry, Claudia Nuñez Mochizaki, Brenda Crabtree Ramirez, Juan Sierra Madero, Yanink Caro Vega, Álvaro López Iñiguez, Ana Fernanda Ramos Menchelli, Paola Alarcón Murra, Geovanna Coello, Guadalupe Muñuzuri Nájera, Rodrigo Ville Benavides, Jessica Mejía, Távata Bejarano, Nancy Sierra, Valeria Fink, Florencia Cahn, Ines Aristegui, Maria Ines Figueroa, Nicolas Doudtchitzky, Javier Mariani, Mariela Ceschel, Gissella Mernies, Agustin Nava, Carina Cesar, Pedro Cahn, Caribbean, Central and South America network for HIV Epidemiology (CCASAnet) of the International epidemiology Databases to Evaluate AIDS (IeDEA)   +95 more
wiley   +1 more source

The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug–drug interaction study

Antimicrobial Agents and Chemotherapy
The mechanism of action of integrase strand transfer inhibitors involves binding to magnesium ions in the active site of the HIV integrase enzyme, making them susceptible to chelation-type drug–drug interactions with metal cation–containing medications ...
Priyanka Arora, Jason T. Hindman, Steve West, John Ling, Ramesh Palaparthy, Dhananjay D. Marathe   +5 more
doaj   +1 more source

Beyond Viral Control: Tenofovir's Hidden Impact on Blood–Brain Barrier Endothelial Cells

Microcirculation, Volume 33, Issue 5, July 2026.
ABSTRACT The blood–brain barrier (BBB) is a dynamic endothelial interface that protects the brain from harmful agents while regulating molecular exchange. Human immunodeficiency virus (HIV) compromises BBB integrity, promoting neurological damage.
Saarah Behardien, Khayelihle Brian Makhathini, Chontrelle Willemse, David Fisher   +3 more
wiley   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, Volume 27, Issue 6, Page 965-978, June 2026.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Emergence of Bictegravir Resistance in a Treatment-Experienced PWH on Functional Monotherapy and Rapid Replacement by an Ancient Wild-Type Strain Following Transient Treatment Interruption

Viruses
A treatment-experienced, highly adherent person living with HIV for over 25 years developed resistance mutations against all four major ART classes, including bictegravir (BIC).
Pietro B. Faré, Gabriela Ziltener, Judith Bergadà Pijuan, Irene A. Abela, Britta L. Hirsch, Michael Huber, Johannes Nemeth, Huldrych F. Günthard   +7 more
doaj   +1 more source

Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study

Scientific Reports
Dolutegravir and bictegravir are second-generation HIV integrase strand transfer inhibitors (INSTIs) that were previously associated with abnormal weight gain.
Julien De Greef, Khoi Nguyen Nguyen, Matthias Van Hul, Anthony Puel, Jean Cyr Yombi, Bernard Vandercam, Anne Vincent, Laure Elens, Leïla Belkhir, Vincent Haufroid, Patrice D. Cani   +10 more
doaj   +1 more source

Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.

, 2022
We present the case of a 78-year-old African American man with a history of human immunodeficiency virus diagnosed in 2007 who was newly diagnosed with pancreatic cancer.
Roa, Pia-Allison E, Bazzi, Rima
core   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living with HIV Aged 50 Years and Older: A Retrospective Analysis of Naïve and Treatment-Experienced Individuals

Viruses
Background: The aging of people living with HIV (PLWH) necessitates antiretroviral regimens (ART) with high efficacy, a favorable safety profile, and minimal drug–drug interactions.
Marcello Trizzino, Luca Pipitò, Floriana Di Figlia, Silvia Bonura, Federica Zimmerhofer, Andrea Cicero, Claudia Gioè, Antonio Cascio   +7 more
doaj   +1 more source